Read by QxMD icon Read

Pancreatic adenoca. Highlights.

shared collection
26 papers 25 to 100 followers
Diego A S Toesca, Amanda J Koong, George A Poultsides, Brendan C Visser, Sigurdis Haraldsdottir, Albert C Koong, Daniel T Chang
With the rapid development of imaging modalities and surgical techniques, the clinical entity representing tumors that are intermediate between resectable and unresectable pancreatic adenocarcinoma has been identified has been termed "borderline resectable" (BR). These tumors are generally amenable for resection but portend an increased risk for positive margins after surgery and commonly necessitate vascular resection and reconstruction. Although there is a lack of consensus regarding the appropriate definition of what constitutes a BR pancreatic tumor, it has been demonstrated that this intermediate category carries a particular prognosis that is in between resectable and unresectable disease...
April 1, 2018: International Journal of Radiation Oncology, Biology, Physics
Rebecca A Snyder, Laura R Prakash, Graciela M Nogueras-Gonzalez, Michael P Kim, Thomas A Aloia, Jean-Nicolas Vauthey, Jeffrey E Lee, Jason B Fleming, Matthew H G Katz, Ching-Wei D Tzeng
BACKGROUND AND OBJECTIVES: Venous patency rates after pancreaticoduodenectomy (PD) with portal vein (PV) resection are not well established, and the oncologic impact of portal vein thrombosis (PVT) is unknown. The primary aim of this study was to determine rates and predictors of PVT after PD with PV resection for pancreatic adenocarcinoma (PDAC). METHODS: A retrospective cohort study was performed on PDAC patients treated with preoperative therapy and PD with PV resection at a high-volume institution (2008-15)...
June 2018: Journal of Surgical Oncology
E Versteijne, J A Vogel, M G Besselink, O R C Busch, J W Wilmink, J G Daams, C H J van Eijck, B Groot Koerkamp, C R N Rasch, G van Tienhoven
BACKGROUND: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival will be skewed. The aim of this study was to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment in resectable or borderline resectable pancreatic cancer. METHODS: MEDLINE, Embase and the Cochrane Library were searched for studies reporting median overall survival by intention to treat in patients with resectable or borderline resectable pancreatic cancer treated with or without neoadjuvant treatment...
July 2018: British Journal of Surgery
Stijn van Roessel, Gyulnara G Kasumova, Omidreza Tabatabaie, Sing Chau Ng, L Bengt van Rijssen, Joanne Verheij, Robert M Najarian, Thomas M van Gulik, Marc G Besselink, Olivier R Busch, Jennifer F Tseng
BACKGROUND: The optimal definition of a margin-negative resection and its exact prognostic significance on survival in resected pancreatic adenocarcinoma remains unknown. This study was designed to assess the relationship between pathological margin clearance, margin type, and survival. METHODS: Patients who underwent pancreaticoduodenectomy with curative intent at two academic institutions, in Amsterdam, the Netherlands, and Boston, Massachusetts, between 2000 and 2014 were retrospectively evaluated...
June 2018: Annals of Surgical Oncology
Neda Hashemi-Sadraei, Olumide B Gbolahan, Hai Salfity, Bert O'Neil, Michael G House, Safi Shahda
OBJECTIVES: The purpose of this study is to describe clinical characteristics and outcomes of patients with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) who achieved pathologic complete response (pCR) following neoadjuvant therapy. MATERIALS AND METHODS: A single institution clinical database for patients with pancreatic ductal adenocarcinoma was queried. Between 2008 and 2014 patients were identified with BRPC and LAPC, who underwent surgical resection after receiving neoadjuvant treatment...
September 29, 2017: American Journal of Clinical Oncology
L Wang, P Dong, W G Wang, B L Tian
BACKGROUND: Numerous distant metastases were not detected preoperatively. Positron emission tomography (PET) has been used for oncology diagnosis recently. However, it remains controversial whether PET modality is a more efficient way in detecting unresectable features for radical resection of pancreatic cancer (PC). This meta-analysis aims to validate the efficiency of PET modalities (including PET and PET/CT) in preoperative assessment of PC, and compare them with computed tomography (CT)...
October 2017: International Journal of Surgery
Sally C Lau, Winson Y Cheung
Pancreatic ductal adenocarcinoma is an infrequent cancer with a high disease related mortality rate, even in the context of early stage disease. Until recently, the rate of death from pancreatic cancer has remained largely similar whereby gemcitabine monotherapy was the mainstay of systemic treatment for most stages of disease. With the discovery of active multi-agent chemotherapy regimens, namely FOLFIRINOX and gemcitabine plus nab-paclitaxel, the treatment landscape of pancreatic cancer is slowly evolving...
July 15, 2017: World Journal of Gastrointestinal Oncology
Chad A Barnes, Ashley N Krepline, Mohammed Aldakkak, Callisia N Clarke, Kathleen K Christians, Abdul H Khan, Bryan C Hunt, Paul S Ritch, Ben George, William A Hall, Beth A Erickson, Douglas B Evans, Susan Tsai
BACKGROUND: Among patients with localized pancreatic cancer (PC), the benefit of adjuvant therapy after neoadjuvant therapy and surgery is unknown. METHODS: Patients with localized PC who completed all intended neoadjuvant therapy and surgery were categorized based on the receipt of adjuvant therapy and by pathologic lymph node status (LN- /LN+ ). RESULTS: Data was available from 234 consecutive patients, 121 (52%) with resectable and 113 (48%) with borderline resectable PC...
November 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
Claudio Bassi, Giovanni Marchegiani, Christos Dervenis, Micheal Sarr, Mohammad Abu Hilal, Mustapha Adham, Peter Allen, Roland Andersson, Horacio J Asbun, Marc G Besselink, Kevin Conlon, Marco Del Chiaro, Massimo Falconi, Laureano Fernandez-Cruz, Carlos Fernandez-Del Castillo, Abe Fingerhut, Helmut Friess, Dirk J Gouma, Thilo Hackert, Jakob Izbicki, Keith D Lillemoe, John P Neoptolemos, Attila Olah, Richard Schulick, Shailesh V Shrikhande, Tadahiro Takada, Kyoichi Takaori, William Traverso, Charles R Vollmer, Christopher L Wolfgang, Charles J Yeo, Roberto Salvia, Marcus Buchler
BACKGROUND: In 2005, the International Study Group of Pancreatic Fistula developed a definition and grading of postoperative pancreatic fistula that has been accepted universally. Eleven years later, because postoperative pancreatic fistula remains one of the most relevant and harmful complications of pancreatic operation, the International Study Group of Pancreatic Fistula classification has become the gold standard in defining postoperative pancreatic fistula in clinical practice. The aim of the present report is to verify the value of the International Study Group of Pancreatic Fistula definition and grading of postoperative pancreatic fistula and to update the International Study Group of Pancreatic Fistula classification in light of recent evidence that has emerged, as well as to address the lingering controversies about the original definition and grading of postoperative pancreatic fistula...
March 2017: Surgery
Shin-Rong Lee, Georgios Gemenetzis, Michol Cooper, Ammar A Javed, John L Cameron, Christopher L Wolfgang, Frederick E Eckhauser, Jin He, Matthew J Weiss
PURPOSE: The goal of this study was to assess the outcomes and characteristics of patients who underwent pancreatectomy for metastatic disease to the pancreas. METHODS: Patients who underwent surgical resection of metastatic disease to the pancreas from 1988 to 2016 were identified using a prospectively maintained database. Data on clinicopathological features and outcomes of these patients were analyzed. Cox proportional hazard models were employed to identify patient-specific risk factors that influence survival...
March 2017: Annals of Surgical Oncology
Nicholas J Petrelli
No abstract text is available yet for this article.
April 2016: Surgical Oncology Clinics of North America
John R Bergquist, Carlos A Puig, Christopher R Shubert, Ryan T Groeschl, Elizabeth B Habermann, Michael L Kendrick, David M Nagorney, Rory L Smoot, Michael B Farnell, Mark J Truty
BACKGROUND: Patient triage in anatomically resectable, early stage pancreatic ductal adenocarcinoma (PDAC) with elevated carbohydrate antigen 19-9 (CA 19-9) remains unclear. We hypothesized that any CA 19-9 elevation indicates biologically borderline resectability. STUDY DESIGN: The National Cancer Data Base (NCDB 2010 to 2012) was reviewed for PDAC patients with reported CA 19-9. Nonsecretors were analyzed separately. Early stage (I/II) patients were stratified by CA 19-9 above or below normal (37 U/mL)...
July 2016: Journal of the American College of Surgeons
Mariam F Eskander, Lindsay A Bliss, Jennifer F Tseng
No abstract text is available yet for this article.
March 2016: Current Problems in Surgery
Michael Tachezy, Florian Gebauer, Monika Janot, Waldemar Uhl, Alessandro Zerbi, Marco Montorsi, Julie Perinel, Mustapha Adham, Christos Dervenis, Christos Agalianos, Giuseppe Malleo, Laura Maggino, Alexander Stein, Jakob R Izbicki, Maximilian Bockhorn
BACKGROUND: The prognosis of patients with liver metastasis is generally considered dismal, and combined resections of the primary tumor and metastasectomies are not recommended. In highly selected patients, however, resections are performed. The evidence for this indication is limited. The aim of the current study was to assess the operative and oncologic outcomes of patients with combined pancreatic and liver resections of synchronous liver metastases. METHODS: In a retrospective analysis of 6 European pancreas centers, we identified 69 patients with pancreatic ductal adenocarcinoma and synchronous liver metastasis who underwent simultaneous pancreas and liver metastasis resections...
July 2016: Surgery
Min Wang, Feng Zhu, Renyi Qin, Shuyou Peng
No abstract text is available yet for this article.
January 5, 2016: Annals of Surgery
F Giovinazzo, G Turri, M H Katz, N Heaton, I Ahmed
BACKGROUND: Pancreatic ductal adenocarcinoma has a poor prognosis without surgery. No standard treatment has yet been accepted for patients with portal-superior mesenteric vein (PV-SMV) infiltration. The present meta-analysis aimed to compare the results of pancreatic resection with PV-SMV resection for suspected infiltration with the results of surgery without PV-SMV resection. METHODS: A systematic search was performed of PubMed, Embase and the Cochrane Library in accordance with PRISMA guidelines from the time of inception to 2013...
February 2016: British Journal of Surgery
Omar M Rashid, Jose M Pimiento, Andrew W Gamenthaler, Phuong Nguyen, Tin T Ha, Tai Hutchinson, Gregory Springett, Sarah Hoffe, Ravi Shridhar, Pamela J Hodul, Brad L Johnson, Karl Illig, Paul A Armstrong, Barbara A Centeno, William J Fulp, Dung-Tsa Chen, Mokenge P Malafa
BACKGROUND: Without prospective data establishing a consensus multimodality approach to borderline resectable pancreatic adenocarcinoma, institutional treatment regimens vary. This study investigated the outcomes of the clinical pathway at the author's institution, which consists of neoadjuvant gemcitabine, docetaxel, capecitabine, and stereotactic radiotherapy followed by surgery. METHODS: The study reviewed all cases that met the National Comprehensive Cancer Network (NCCN) diagnostic criteria for borderline resectable pancreatic adenocarcinoma from 1 January 2006, to 31 December 2013...
April 2016: Annals of Surgical Oncology
Shuji Suzuki, Toru Furukawa, Nana Oshima, Wataru Izumo, Kyoko Shimizu, Masakazu Yamamoto
BACKGROUND: This retrospective study aimed to evaluate clinicopathological findings of remnant pancreatic cancers in survivors of invasive ductal adenocarcinomas of the pancreas (PDAC). METHODS: A group of 23 patients out of 826 who had curative resections for PDAC between 1980 and 2011 was identified and treated for metachronous pancreatic cancer. RESULTS: The following tubular adenocarcinomas were found at the first surgery: 3 well differentiated, 17 moderately differentiated, 1 papillary, and 1 poorly differentiated...
April 2016: World Journal of Surgery
Farzad Alemi, Adnan Alseidi, W Scott Helton, Flavio G Rocha
No abstract text is available yet for this article.
September 2015: Current Problems in Surgery
M Ducreux, A Sa Cuhna, C Caramella, A Hollebecque, P Burtin, D Goéré, T Seufferlein, K Haustermans, J L Van Laethem, T Conroy, D Arnold
No abstract text is available yet for this article.
September 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
2015-10-01 09:34:49
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"